Long-Term Survival Benefit Shown With Enzalutamide Plus ADT in mHSPC

Neal Shore, MD, FACS discusses results from a post-hoc analysis of the phase 3 ARCHES trial.

Neal Shore, MD, FACS the US chief medical officer of Surgery and Oncology at GenesisCare and the director and certified principal investigator at the Carolina Urologic Research Center, discusses results from a post-hoc analysis of the phase 3 ARCHES trial (NCT02677896). The analysis assessed overall survival in patients with prior local therapy, defined as previous radical prostatectomy and/or radiation therapy to the prostate area.


The results were presented during a moderated poster session at the AUA 2022 Annual Meeting, in New Orleans, LA. The analysis demonstrated that enzalutamide (enza; Xtandi) plus androgen deprivation therapy (ADT) improved recurrence-free survival (RFS) and OS vs ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The hazard ratio for the difference between enza plus ADT vs ADT alone was 0.66 (95% CI, 0.53, 0.81; P <0.0001).


According to Shore, in terms of OS and RFS, patients with de novo or recurrent mHSPC did better with the combination, and the positive findings were irrespective of prior treatment with either surgery or radiation, Shore adds.


Transcription:


0:08 | I think the most important thing to highlight is that if you have patients who have either de novo mHSPC, or recurrent mHSPC, whether they've had an active treatment for the primary, the prostate, whether it was a surgical extirpation or radiation or both, regardless [of] when they go on to develop metastatic disease.


0:33 | The patients did remarkably better from an RFS and OS standpoint for those who received combination ADT and enza versus monotherapy ADT.